CAR-T Therapy Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

CAR-T Therapy Market to 2027 - Global Analysis and Forecasts by Targeted Antigen (CD 19,BCMA,HER2,GD2,CD 20,CD22,CD30,CD33,HER1 and Others); Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer and Others)

Report Code: TIPRE00003731 | No. of Pages: 150 | Category: Medical Device | Status: Upcoming
MARKET INTRODUCTION
CAR-T Therapies are recently preferred more over surgeries, chemotherapy and radiation. This therapy targets the cancer cells and strengthens the patient's immune system against tumor. This is a type of therapy where the T- Cells derived from the patient's blood is modified in the laboratory by adding a special protein receptor on the T-Cells that attack cancer cells.

MARKET DYNAMICS
The CAR-T Therapy market is anticipated to grow in the forecast period owing to driving factors such as rising number of patients showing failure to alternative treatments, increasing number of cancer patients and development of new and effective therapies. Nevertheless, side effects such as Cytokine release syndrome and neurological problems such as seizures, delirium and others can be a hindrance in the market growth during the forecast period.

MARKET SCOPE
The "Global CAR-T Therapy Market Analysis to 2027" is a specialized and in-depth study of the Biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of CAR-T Therapy market with detailed market segmentation by Dosage, Route of Administration, Application and geography. The global CAR-T Therapy market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading CAR-T Therapy market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global CAR-T Therapy market is segmented on the basis of Targeted Antigen and Therapeutic Application. On the basis of Targeted Antigen the market is segments into CD 19,BCMA,HER2,GD2,CD 20,CD22,CD30,CD33,HER1 and Others. On the basis of Therapeutic Application the market is segmented as Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer and Others
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global CAR-T Therapy market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The CAR-T Therapy market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting CAR-T Therapy market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the CAR-T Therapy market in these regions.

MARKET PLAYERS
The reports cover key developments in the CAR-T Therapy Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from CAR-T Therapy Market are anticipated to lucrative growth opportunities in the future with the rising demand for CAR-T Therapy in the global market. Below mentioned is the list of few companies engaged in the CAR-T Therapy market.

The report also includes the profiles of key CAR-T Therapy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Novartis International AG
  • Kite Pharma, Inc. (Gilead Sciences, Inc.)
  • Juno Therapeutics (Celgene Corporation)
  • Bluebird Bio, Inc. (Celgene Corporation)
  • Sorrento Therapeutics Inc.
  • Mustang Bio, Inc
  • Aurora Biopharma Inc.
  • Legend Biotech (Genscript Biotech Corporation)
  • Pfizer, Inc.
  • CARsgen Therapeutics, Ltd.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 CAR-T Cell Therapy Market - By Targeted Antigen
1.3.2 CAR-T Cell Therapy Market - By Therapeutic Application
1.3.3 CAR-T Cell Therapy Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. CAR-T CELL THERAPY MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CAR-T CELL THERAPY MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CAR-T CELL THERAPY MARKET - GLOBAL MARKET ANALYSIS
6.1. CAR-T CELL THERAPY - GLOBAL MARKET OVERVIEW
6.2. CAR-T CELL THERAPY - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CAR-T CELL THERAPY MARKET - REVENUE AND FORECASTS TO 2027 - TARGETED ANTIGEN
7.1. OVERVIEW
7.2. TARGETED ANTIGEN MARKET FORECASTS AND ANALYSIS
7.3. CD 19
7.3.1. Overview
7.3.2. CD 19 Market Forecast and Analysis
7.4. BCMA
7.4.1. Overview
7.4.2. BCMA Market Forecast and Analysis
7.5. HER2
7.5.1. Overview
7.5.2. HER2 Market Forecast and Analysis
7.6. GD2
7.6.1. Overview
7.6.2. GD2 Market Forecast and Analysis
7.7. CD 20
7.7.1. Overview
7.7.2. CD 20 Market Forecast and Analysis
7.8. CD22
7.8.1. Overview
7.8.2. CD22 Market Forecast and Analysis
7.9. CD30
7.9.1. Overview
7.9.2. CD30 Market Forecast and Analysis
7.10. CD33
7.10.1. Overview
7.10.2. CD33 Market Forecast and Analysis
7.11. HER1 AND OTHERS
7.11.1. Overview
7.11.2. HER1 and Others Market Forecast and Analysis
8. CAR-T CELL THERAPY MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC APPLICATION
8.1. OVERVIEW
8.2. THERAPEUTIC APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ACUTE LYMPHOCYTIC LEUKEMIA
8.3.1. Overview
8.3.2. Acute Lymphocytic Leukemia Market Forecast and Analysis
8.4. CHRONIC LYMPHOCYTIC LEUKEMIA
8.4.1. Overview
8.4.2. Chronic Lymphocytic Leukemia Market Forecast and Analysis
8.5. DIFFUSE LARGE B-CELL LYMPHOMA
8.5.1. Overview
8.5.2. Diffuse Large B-Cell Lymphoma Market Forecast and Analysis
8.6. FOLLICULAR LYMPHOMA
8.6.1. Overview
8.6.2. Follicular Lymphoma Market Forecast and Analysis
8.7. MULTIPLE MYELOMA
8.7.1. Overview
8.7.2. Multiple Myeloma Market Forecast and Analysis
8.8. GLIOBLASTOMA
8.8.1. Overview
8.8.2. Glioblastoma Market Forecast and Analysis
8.9. SARCOMA
8.9.1. Overview
8.9.2. Sarcoma Market Forecast and Analysis
8.10. NEUROBLASTOMA
8.10.1. Overview
8.10.2. Neuroblastoma Market Forecast and Analysis
8.11. ACUTE MYELOID LEUKEMIA
8.11.1. Overview
8.11.2. Acute Myeloid Leukemia Market Forecast and Analysis
8.12. BREAST CANCER
8.12.1. Overview
8.12.2. Breast Cancer Market Forecast and Analysis
8.13. PANCREATIC CANCER
8.13.1. Overview
8.13.2. Pancreatic Cancer Market Forecast and Analysis
8.14. HEPATOCELLULAR CARCINOMA
8.14.1. Overview
8.14.2. Hepatocellular Carcinoma Market Forecast and Analysis
8.15. COLORECTAL CANCER AND OTHERS
8.15.1. Overview
8.15.2. Colorectal Cancer and Others Market Forecast and Analysis
9. CAR-T CELL THERAPY MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America CAR-T Cell Therapy Market Overview
9.1.2 North America CAR-T Cell Therapy Market Forecasts and Analysis
9.1.3 North America CAR-T Cell Therapy Market Forecasts and Analysis - By Targeted Antigen
9.1.4 North America CAR-T Cell Therapy Market Forecasts and Analysis - By Therapeutic Application
9.1.5 North America CAR-T Cell Therapy Market Forecasts and Analysis - By Countries
9.1.5.1 United States CAR-T Cell Therapy Market
9.1.5.1.1 United States CAR-T Cell Therapy Market by Targeted Antigen
9.1.5.1.2 United States CAR-T Cell Therapy Market by Therapeutic Application
9.1.5.2 Canada CAR-T Cell Therapy Market
9.1.5.2.1 Canada CAR-T Cell Therapy Market by Targeted Antigen
9.1.5.2.2 Canada CAR-T Cell Therapy Market by Therapeutic Application
9.1.5.3 Mexico CAR-T Cell Therapy Market
9.1.5.3.1 Mexico CAR-T Cell Therapy Market by Targeted Antigen
9.1.5.3.2 Mexico CAR-T Cell Therapy Market by Therapeutic Application
9.1.5.4 US CAR-T Cell Therapy Market
9.1.5.4.1 US CAR-T Cell Therapy Market by Targeted Antigen
9.1.5.4.2 US CAR-T Cell Therapy Market by Therapeutic Application
9.2. EUROPE
9.2.1 Europe CAR-T Cell Therapy Market Overview
9.2.2 Europe CAR-T Cell Therapy Market Forecasts and Analysis
9.2.3 Europe CAR-T Cell Therapy Market Forecasts and Analysis - By Targeted Antigen
9.2.4 Europe CAR-T Cell Therapy Market Forecasts and Analysis - By Therapeutic Application
9.2.5 Europe CAR-T Cell Therapy Market Forecasts and Analysis - By Countries
9.2.5.1 Germany CAR-T Cell Therapy Market
9.2.5.1.1 Germany CAR-T Cell Therapy Market by Targeted Antigen
9.2.5.1.2 Germany CAR-T Cell Therapy Market by Therapeutic Application
9.2.5.2 France CAR-T Cell Therapy Market
9.2.5.2.1 France CAR-T Cell Therapy Market by Targeted Antigen
9.2.5.2.2 France CAR-T Cell Therapy Market by Therapeutic Application
9.2.5.3 Italy CAR-T Cell Therapy Market
9.2.5.3.1 Italy CAR-T Cell Therapy Market by Targeted Antigen
9.2.5.3.2 Italy CAR-T Cell Therapy Market by Therapeutic Application
9.2.5.4 Spain CAR-T Cell Therapy Market
9.2.5.4.1 Spain CAR-T Cell Therapy Market by Targeted Antigen
9.2.5.4.2 Spain CAR-T Cell Therapy Market by Therapeutic Application
9.2.5.5 United Kingdom CAR-T Cell Therapy Market
9.2.5.5.1 United Kingdom CAR-T Cell Therapy Market by Targeted Antigen
9.2.5.5.2 United Kingdom CAR-T Cell Therapy Market by Therapeutic Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific CAR-T Cell Therapy Market Overview
9.3.2 Asia-Pacific CAR-T Cell Therapy Market Forecasts and Analysis
9.3.3 Asia-Pacific CAR-T Cell Therapy Market Forecasts and Analysis - By Targeted Antigen
9.3.4 Asia-Pacific CAR-T Cell Therapy Market Forecasts and Analysis - By Therapeutic Application
9.3.5 Asia-Pacific CAR-T Cell Therapy Market Forecasts and Analysis - By Countries
9.3.5.1 Australia CAR-T Cell Therapy Market
9.3.5.1.1 Australia CAR-T Cell Therapy Market by Targeted Antigen
9.3.5.1.2 Australia CAR-T Cell Therapy Market by Therapeutic Application
9.3.5.2 China CAR-T Cell Therapy Market
9.3.5.2.1 China CAR-T Cell Therapy Market by Targeted Antigen
9.3.5.2.2 China CAR-T Cell Therapy Market by Therapeutic Application
9.3.5.3 India CAR-T Cell Therapy Market
9.3.5.3.1 India CAR-T Cell Therapy Market by Targeted Antigen
9.3.5.3.2 India CAR-T Cell Therapy Market by Therapeutic Application
9.3.5.4 Japan CAR-T Cell Therapy Market
9.3.5.4.1 Japan CAR-T Cell Therapy Market by Targeted Antigen
9.3.5.4.2 Japan CAR-T Cell Therapy Market by Therapeutic Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa CAR-T Cell Therapy Market Overview
9.4.2 Middle East and Africa CAR-T Cell Therapy Market Forecasts and Analysis
9.4.3 Middle East and Africa CAR-T Cell Therapy Market Forecasts and Analysis - By Targeted Antigen
9.4.4 Middle East and Africa CAR-T Cell Therapy Market Forecasts and Analysis - By Therapeutic Application
9.4.5 Middle East and Africa CAR-T Cell Therapy Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa CAR-T Cell Therapy Market
9.4.5.1.1 South Africa CAR-T Cell Therapy Market by Targeted Antigen
9.4.5.1.2 South Africa CAR-T Cell Therapy Market by Therapeutic Application
9.4.5.2 Saudi Arabia CAR-T Cell Therapy Market
9.4.5.2.1 Saudi Arabia CAR-T Cell Therapy Market by Targeted Antigen
9.4.5.2.2 Saudi Arabia CAR-T Cell Therapy Market by Therapeutic Application
9.4.5.3 U.A.E CAR-T Cell Therapy Market
9.4.5.3.1 U.A.E CAR-T Cell Therapy Market by Targeted Antigen
9.4.5.3.2 U.A.E CAR-T Cell Therapy Market by Therapeutic Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America CAR-T Cell Therapy Market Overview
9.5.2 South and Central America CAR-T Cell Therapy Market Forecasts and Analysis
9.5.3 South and Central America CAR-T Cell Therapy Market Forecasts and Analysis - By Targeted Antigen
9.5.4 South and Central America CAR-T Cell Therapy Market Forecasts and Analysis - By Therapeutic Application
9.5.5 South and Central America CAR-T Cell Therapy Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil CAR-T Cell Therapy Market
9.5.5.1.1 Brazil CAR-T Cell Therapy Market by Targeted Antigen
9.5.5.1.2 Brazil CAR-T Cell Therapy Market by Therapeutic Application
9.5.5.2 Argentina CAR-T Cell Therapy Market
9.5.5.2.1 Argentina CAR-T Cell Therapy Market by Targeted Antigen
9.5.5.2.2 Argentina CAR-T Cell Therapy Market by Therapeutic Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. CAR-T CELL THERAPY MARKET, KEY COMPANY PROFILES
11.1. NOVARTIS INTERNATIONAL AG
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. KITE PHARMA, INC. (GILEAD SCIENCES, INC.)
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. JUNO THERAPEUTICS
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. BLUEBIRD BIO, INC. (CELGENE CORPORATION)
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. SORRENTO THERAPEUTICS INC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. MUSTANG BIO, INC
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. AURORA BIOPHARMA INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. LEGEND BIOTECH (GENSCRIPT BIOTECH CORPORATION)
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. PFIZER, INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. CARSGEN THERAPEUTICS, LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TE
The List of Companies

1. Novartis International AG
2. Kite Pharma, Inc. (Gilead Sciences, Inc.)
3. Juno Therapeutics (Celgene Corporation)
4. Bluebird Bio, Inc. (Celgene Corporation)
5. Sorrento Therapeutics Inc.
6. Mustang Bio, Inc
7. Aurora Biopharma Inc.
8. Legend Biotech (Genscript Biotech Corporation)
9. Pfizer, Inc.
10. CARsgen Therapeutics, Ltd.
Select License Type
USD $3000
USD $4550
USD $6550
USD $8550

Free

20%

customization on Pre-Booking
Pre Book